Larimar Therapeutics (LRMR) Common Equity (2013 - 2026)

Larimar Therapeutics (LRMR) has reported Common Equity for 14 consecutive years, with $127.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 6.28% year-over-year to $127.4 million; the trailing twelve-month figure through Jun 2026 stood at $127.4 million (up 6.28% YoY), and the FY2025 full-year result was $78.1 million, down 54.55% from the prior year.
• Common Equity grew to $127.4 million in Q2 2026 per LRMR's latest filing, from $78.1 million in the prior quarter.
• Across five years, Common Equity topped out at $230.8 million in Q1 2024 and bottomed at $50.1 million in Q2 2022.
• Historically, Common Equity has averaged $125.8 million across 5 years, with a median of $118.7 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Common Equity surged 117.28% in 2024, then plunged 54.55% in 2025.
• Over 5 years, Common Equity stood at $110.9 million in 2022, then declined by 26.31% to $81.7 million in 2023, then surged by 110.24% to $171.8 million in 2024, then slumped by 54.55% to $78.1 million in 2025, then soared by 63.13% to $127.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $127.4 million, $78.1 million, and $139.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.